HomeGeneticsConditionLeber hereditary optic neuropathy
Back to Condition
Leber hereditary optic neuropathy
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Leber Hereditary Optic Neuropathy (LHON)

Leber hereditary optic neuropathy is a maternally inherited mitochondrial disorder that causes sudden, painless central vision loss, predominantly striking young adult males.

Overview

Leber hereditary optic neuropathy (LHON) is a genetic form of vision loss caused by degeneration of the optic nerve. It most commonly emerges during a person's teens or twenties, though symptom onset can occasionally occur in early childhood or later in adulthood. For reasons not fully understood, males develop visual failure far more frequently than females.

Symptoms

Classic Ocular Features

Visual failure in LHON typically presents with the following characteristics:

  • Initial Blurring and Clouding: The first signs are painless blurring and loss of sharpness in central vision. Symptoms may begin simultaneously in both eyes or start in one eye, with the second eye becoming affected within several weeks or months.
  • Severe Central Vision Loss: Visual acuity rapidly deteriorates, alongside profound loss of color vision. Central vision—critical for reading, driving, and facial recognition—is primarily lost. Peripheral vision usually remains intact.
  • Optic Nerve Atrophy: Visual deficits stem from the death of retinal ganglion cells and axonal loss within the optic nerve, which relays visual signals from the eye to the brain.
  • Permanence: While a small percentage of patients experience slight visual recovery over time, the visual impairment is permanent and severe in most cases.

LHON Plus

While vision loss is typically the sole clinical manifestation, some families experience an extended phenotype designated as LHON plus. Additional features may include:

  • Movement disorders and tremors
  • Cardiac conduction defects (abnormalities in the electrical rhythm of the heart)
  • Neurological deficits resembling multiple sclerosis, such as muscle weakness, numbness, and impaired motor coordination

Frequency

The worldwide prevalence of LHON remains undetermined for most populations. In northeast England and Finland, epidemiological surveys estimate that the disorder affects approximately 1 in 30,000 to 1 in 50,000 people.

Causes

LHON is caused by point mutations in mitochondrial genes, primarily:

  • MT-ND1
  • MT-ND4
  • MT-ND4L
  • MT-ND6

These genes are located in mitochondrial DNA (mtDNA). Mitochondria are the specialized structures inside cells responsible for converting nutrients into usable cellular energy. The proteins encoded by these four genes form structural parts of complex I, an enzyme complex within the mitochondrial respiratory chain that processes fats, sugars, and oxygen to produce energy. Mutations disrupt this oxidative phosphorylation process, triggering targeted cellular death among the sensitive fibers of the optic nerve.

Penetrance and Modifying Factors

A significant percentage of individuals carrying a causative mtDNA mutation never develop clinical vision loss. More than 50 percent of males and over 85 percent of females who carry a pathogenic mutation remain symptom-free throughout life. This incomplete penetrance indicates that other elements influence disease onset:

  • Environmental Influences: Exposures such as tobacco smoking and excessive alcohol consumption have been implicated as potential triggers, though research findings remain varied.
  • Nuclear Modifier Genes: Scientists continue to investigate whether variations in secondary nuclear genes determine why certain carriers develop visual loss while others do not.

Inheritance

LHON follows a pattern of mitochondrial inheritance, also referred to as maternal inheritance:

  • Mitochondria are transmitted exclusively through maternal egg cells; sperm cells do not contribute mitochondria to the fertilized embryo. Consequently, only females can pass mtDNA mutations to their offspring.
  • An affected or carrier mother will pass the mutation to all of her children, both male and female.
  • An affected male cannot transmit the mutation to his biological children.

Because many mutation carriers experience no visual deterioration, individuals newly diagnosed with LHON frequently report no known family history of the disease.

Other Names

  • Hereditary optic neuroretinopathy
  • Leber hereditary optic atrophy
  • Leber optic atrophy
  • Leber's hereditary optic neuropathy
  • Leber's optic atrophy
  • Leber's optic neuropathy
  • LHON

Frequently Asked Questions

The quinone analog idebenone (Raxone) is the only medication approved in several countries; it may improve visual acuity if started within months of onset, especially in patients with the m.14484T>C mutation. Gene‑replacement trials are ongoing, but no definitive cure exists. Low‑vision rehabilitation, protective sunglasses, and avoidance of toxic exposures are essential supportive measures.
Smoking, excessive alcohol, certain antibiotics (e.g., linezolid), and drugs that impair mitochondrial function are known precipitants. Maintaining a balanced diet, avoiding toxin exposure, and managing systemic illnesses (e.g., diabetes) can reduce the likelihood of conversion from carrier to symptomatic disease.
Key clues include rapid loss of central acuity and color vision in a young adult, often bilateral or sequential, with a normal fundus early on that later shows optic disc pallor. A positive maternal family history and confirmation of one of the three common mitochondrial DNA mutations (m.11778G>A, m.14484T>C, m.3460G>A) on genetic testing clinches the diagnosis.
LHON is maternally inherited, so every child of an affected mother will inherit the mitochondrial mutation (100 % transmission). However, only about 30‑50 % of male carriers develop visual loss, compared with 10‑15 % of female carriers, reflecting incomplete penetrance and a strong gender bias whose mechanism is not fully understood.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA